Table 1 Baseline characteristics of BARI 2D CABG strata patients randomized to intensive medical therapy with and without death/MI/stroke
Variable | No death/MI/stroke (N = 270) | Death/MI/stroke (N = 115) | ||
|---|---|---|---|---|
Age | 62.07 | ± 8.01 | 65.46 | ± 8.21 |
Male, no. (%) | 204 | (76%) | 93 | (81%) |
White, no. (%) | 206 | (76%) | 87 | (76%) |
Insulin sensitizing arm, no. (%) | 132 | (49%) | 59 | (51%) |
History of insulin use, no. (%) | 60 | (22%) | 34 | (30%) |
History of MI, no. (%) | 109 | (41%) | 36 | (32%) |
History of CHF, no. (%) | 7 | (3%) | 9 | (8%) |
Hypertension, no. (%) | 216 | (81%) | 99 | (88%) |
Hypercholesterolemia, no. (%) | 221 | (83%) | 84 | (74%) |
Cerebrovascular accident, TIA, no. (%) | 15 | (6%) | 13 | (12%) |
Prior revascularization, no. (%) | 34 | (13%) | 22 | (19%) |
Current smoker, no. (%) | 29 | (11%) | 12 | (10%) |
Angina equivalent, no. (%) | 155 | (58%) | 67 | (59%) |
Angina class, no. (%) | ||||
Stable 1, 2 | 137 | (51%) | 48 | (42%) |
Stable 3, 4 | 12 | (4%) | 9 | (8%) |
Unstable | 11 | (4%) | 6 | (5%) |
No angina | 110 | (41%) | 52 | (45%) |
Weight (kg) | 85.33 | ± 18.57 | 86.12 | ± 18.68 |
BMI | 30.74 | ± 4.97 | 30.59 | ± 5.41 |
Systolic blood pressure (mmHg) | 134.73 | ± 19.95 | 138.79 | ± 21.02 |
Diastolic blood pressure (mmHg) | 76.80 | ± 10.28 | 75.82 | ± 10.95 |
Ankle brachial index (ABI) | 1.04 | ± 0.23 | 1.03 | ± 0.32 |
Serum creatinine (mg/dl) | 1.03 | ± 0.26 | 1.12 | ± 0.27 |
Urine albumin/creatinine ratio (mg/g), median (Q1, Q3) | 12.4 | (4.9, 55.6) | 20.8 | (7.7, 124.6) |
Circulating insulin (IU/ml), median (Q1, Q3) | 9.1 | (5.0, 18.0) | 9.9 | (5.5, 20.0) |
HbA1c (%) | 7.79 | ± 1.67 | 7.94 | ± 1.60 |
HbA1c lower than 7%, no. (%) | 107 | (40%) | 33 | (29%) |
HDL cholesterol (mg/dl) | 38.24 | ± 9.23 | 37.59 | ± 9.95 |
LDL cholesterol (mg/dl) | 98.22 | ± 34.05 | 94.79 | ± 38.75 |
Triglycerides (mg/dl), median (Q1, Q3) | 160.0 | (118.0, 220.0) | 153.5 | (108.5, 235.5) |
Myocardial jeopardy | 57.10 | ± 21.34 | 62.97 | ± 22.54 |
Non-sublingual nitrate, no. (%) | 88 | (33%) | 39 | (34%) |
Anti-platelet, no. (%) | 37 | (14%) | 18 | (16%) |
Aspirin, no. (%) | 240 | (90%) | 102 | (89%) |
Statin, no. (%) | 204 | (76%) | 89 | (78%) |
ACE/ARB, no. (%) | 206 | (77%) | 94 | (82%) |
Beta-blocker, no. (%) | 206 | (77%) | 84 | (73%) |
Aspirin, statin, ACE/ARB, beta-blocker, no. (%) | 121 | (45%) | 59 | (51%) |